Standardization of Cardiac 123I-mIBG scintigraphy is necessary to improve its clinical acceptance and utility in heart failure and cardio-oncology.
Answers are grounded in this paper and cite their sources.
Supports further 123I-mIBG evaluation in CHF; leaves open routine adoption pending higher-level evidence.
Cardiac adrenergic imaging has a great potential in a wide variety of clinical applications. Cardiac 123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy has a key role to assess chronic heart failure (CHF) by risk stratifying patients for cardiac events. The mIBG is a norepinephrine (NE) analogue that can evaluate cardiac sympathetic activity by assessing the down expression of β-adrenergic receptor (β-AR) in CHF. Furthermore, 123I-mIBG scintigraphy in combination with other parameters of left ventricular function can be used to identify the best responder for implantable cardiac devices, as well as to assess oncological cardiotoxicity. Despite its usefulness, 123I-mIBG scintigraphy is not widely performed because of the lack of standardization between different institutions. Thus, standardization and validation may contribute to its acceptance in clinical setting.
No takes yet. Share an insight, caveat, or question.
Rocha et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: